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Abstract
Background: The aim of the current study was to provide general practitioners with an overview
of the available treatment options for Alzheimer's disease (AD). Since general practitioners provide
the majority of medical care for AD patients, they should be well versed in treatment options that
can improve function and slow the progression of symptoms.
Design: Biomedical literature related to acetylcholinesterase inhibitors (AChEIs) was surveyed. In
the United States, there are four AChEIs approved for the treatment of AD: tacrine, donepezil,
rivastigmine, and galantamine. There are other agents under investigation, but at present, AChEIs
are the only approved drug category for AD treatment.
Measurements and Main Results: AD is becoming a major public health concern and
underdiagnosis is a significant problem (with only about half of AD patients being diagnosed and
only half of those diagnosed actually being treated). Clinical trials have demonstrated that patients
with AD who do not receive active treatment decline at more rapid rates than those who do.
Conclusions: Given that untreated AD patients show decline in three major areas (cognition,
behavior, and functional ability), if drug treatment is able to improve performance, maintain baseline
performance over the long term, or allow for a slower rate of decline in performance, each of these
outcomes should be viewed a treatment success.
Background
Alzheimer's disease (AD) is a progressive neurodegenera-
tive disorder that is clinically characterized by loss of
memory and progressive deficits in other cognitive do-
mains. Alterations in behavior, such as apathy, agitation,
and psychosis, are also cardinal clinical features. Together,
the cognitive and behavioral alterations that define the
clinical syndrome of AD underlie the progressive func-
tional decline that all patients show in performing activi-
ties of daily living (ADL). Aside from its direct effects on
patients, AD leads to a decreased quality of life and an in-
creased burden on caregivers.
AD is the most common cause of dementia in people 65
years and older: it affects 10% of people over the age of 65
and 50% of people over the age of 85 [1]. The number of
patients with AD is expected to rise with increasing life ex-
pectancy and growth in the aging population. AD will po-
tentially be the most overwhelming public health
problem of this century. In the United States alone, the
projected prevalence is over 4 million and is expected to
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reach 14 million in the next 50 years [1]. AD is one of sev-
eral causes of dementia, accounting for approximately
two thirds or more of all dementia cases [2]. Vascular de-
mentia (VaD) accounts for approximately 15% of all de-
mentias [2], while some patients may also display
dementia of mixed etiology (AD/VaD). A collaborative
study of the incidence of dementia and major subtypes
was conducted in Europe. The findings confirmed that AD
is the most prevalent dementing disorder across all ages
and with a higher incidence in women over 80 years of age
[3]. Since AD is the most common and best understood
cause of dementia, it will be the focus of this review. A
PubMed search was conducted with an emphasis on liter-
ature from the past 10 years.
Underdiagnosis and undertreatment of AD are significant
problems in the present clinical approach to the disorder.
Approximately 50% of people with AD are actually diag-
nosed, and only 50% of those diagnosed are actually be-
ing treated [1]; 12% of patients diagnosed with AD are
being prescribed acetylcholinesterase inhibitors (AChEIs),
the established mainstay of treatment [4]. The remainder
of those treated are generally receiving psychotropic med-
ications and other putative anti-dementia agents such as
gingko biloba. Therapy for AD is initiated by general prac-
titioners in more than 40% of cases, as they are the clini-
cians providing the majority of medical care for these
patients [5]. It has been increasingly recognized that early
diagnosis and comprehensive management of cognitive
and behavioral symptoms are crucial in optimizing dis-
ease management. Worthy and attainable goals of treat-
ment include improvement in cognition and behavior or
prolonged stabilization of function for as long as 1 year
[6]. Additionally, thoughtful care of the patient includes
careful attention to the needs of the caregiver, who may be
especially burdened by disease progression.
The disease process
AD progresses through several clinical stages (Figure 1).
Loss of recent memory, or forgetfulness, is the most com-
mon presenting symptom. This is often accompanied, or
shortly followed by, personality and behavioral changes,
including disinterest in hobbies and social activities.
Complex tasks that involve executive functioning – such
as the management of finances, using household appli-
ances, and performing household chores – are often im-
paired early in the disease, whereas basic ADL – such as
grooming and hygiene, toileting, and feeding – are not af-
fected until the dementia is more advanced. Impaired pa-
tients will eventually develop decline in other cognitive
realms. These include navigational ability (visual-spatial
function), recognition of common items (gnosis), and
motor programming (praxis) [7].
Multiple risk factors have been proposed for the develop-
ment of AD. It is generally agreed that advancing age and
family history of dementia are the major risk factors in
typical, late-onset AD [2]. Genetic factors can also be a
contributing risk in early-onset disease. While the role of
apolipoprotein E (APOE) in AD pathology is unknown,
there is a correlation between the risk of AD and APOE
genotype [8]. The APOE-4 allele has been most closely as-
sociated with increasing the risk of AD by three- to
fourfold.
AD is a complex neurologic disease that is diagnosed by
clinical presentation; however, there are three consistent
neuropathologic hallmarks of the disorder that are gener-
ally noted on postmortem brain examination: amyloid-
rich senile plaques [9], neurofibrillary tangles [10], and
neuronal degeneration. The primary cause of AD is still
speculative, but AD pathology includes evidence of neuro-
nal cell dysfunction either caused by or resulting in neu-
rofibrillary tangles and/or β-amyloid plaques. In recent
years, significant research attention has also been devoted
to the roles of inflammation, free radical formation, and
oxidative cell damage in the pathogenesis of AD. The pro-
gression of AD is related to the disease's effect on neuronal
circuitry. Short-term memory loss, usually the first symp-
tom of the disease, reflects a disruption of signaling be-
tween the hippocampus and entorhinal cortex, adjacent
regions of the brain that are thought to be required for ear-
ly establishment of memory [11]. As AD advances in se-
verity, neuronal signaling in the neocortical areas required
for cognitive function and long-term memory storage are
affected [11]. AD exhibits a large impact on neurotrans-
mission: the most prominent neurotransmitter changes
are cholinergic. The effects of AD on the cholinergic sys-
tem include reduced activity of choline acetyltransferase
(ie, reduced synthesis of acetylcholine [ACh]) [12], re-
duced number of cholinergic neurons in late AD (particu-
larly in the basal forebrain) [13], and selective loss of
nicotinic receptor subtypes in the hippocampus and cor-
tex [12].
Review
Approved drugs for the treatment of AD
ACh is the major neurotransmitter affected in AD [12]. Its
pharmacology is a consequence of its interrelationship
with acetylcholinesterase (AChE), butyrylcholinesterase
(BuChE), muscarinic receptors, and nicotinic receptors.
AChEIs are the only drug class currently approved in the
United States for the treatment of AD. AChEIs block the
esterase-mediated metabolism of ACh to choline and ace-
tate and result in increased ACh in the synaptic cleft and
increased availability of ACh for postsynaptic and presyn-
aptic cholinergic receptors [14]. There are four AChEIs
currently available in the United States: tacrine (Cognex®,
1993), donepezil (Aricept®, 1996), rivastigmine (Exelon®,Annals of General Hospital Psychiatry 2003, 2 http://www.general-hospital-psychiatry.com/content/2/1/1
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2000), and galantamine (Reminyl®, 2001). Table 1 iden-
tifies prescription share and volume. Each of these agents
has undergone extensive clinical trial evaluation through-
out the world. Drug efficacy versus placebo has been dem-
onstrated consistently in trials ranging in duration from
12 to 52 weeks. Generally, the majority of clinical trials
conducted to establish the efficacy of treating AD with this
class of agents have adopted similar outcome measures.
The standard psychometric tool used to assess cognition
in the majority of these studies is the Alzheimer's Disease
Assessment Scale (ADAS) [15]. The section of the scale
from which scores are most frequently reported is the cog-
nitive subscale (ADAS-cog). In addition to the ADAS-cog,
the AD clinical trials also utilize quantified clinical im-
pressions of the patient by a study investigator. These data
usually are gleaned from direct examination of the study
subject as well as from a caregiver interview. These clinical
impressions are most often reported as a Clinical Global
Impression (CGI) or Clinician Interview-Based Impres-
sion of Change (CIBIC).
While the four available AChEIs are all members of a com-
mon drug class, they exhibit many individual differences.
The characteristics of these agents are summarized in Ta-
ble 2.
Treatment with AChEIs
Tacrine
Tacrine was the first AChEI licensed for the treatment of
AD. It is a centrally active aminoacridine and is a reversi-
ble cholinesterase inhibitor. It is currently used in the
United States as a last-line agent because of a high inci-
Figure 1
AD progresses through distinct stages.Annals of General Hospital Psychiatry 2003, 2 http://www.general-hospital-psychiatry.com/content/2/1/1
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dence of hepatotoxicity, as evidenced by elevated serum
transaminases. Additionally, the use of tacrine has been
limited by its relatively short half-life that necessitates
dosing at four times per day. Tacrine's efficacy was dem-
onstrated conclusively in several large, multi-site clinical
trials. Doses of at least 80 mg/day are required to achieve
a modest degree of efficacy as measured by the ADAS-cog
scale, activities of daily living scales, and clinical global
impressions of change as assessed by clinicians and car-
egivers [16–18].
Donepezil
Donepezil is currently the most prescribed agent for AD,
accounting for approximately 38% of prescriptions [19].
It is a noncompetitive, reversible AChEI with a long half-
life (approximately 70 hours), which allows for once-dai-
ly dosing of 5 or 10 mg [20]. In multiple clinical trials,
donepezil was well tolerated, with the majority of adverse
events being mild, dose-related, and gastrointestinal in
nature (Table 3) [21–23].
The efficacy of donepezil in improving/maintaining cog-
nition has been demonstrated in a 15-week and two 24-
week clinical trials [21–23]. Doses of 5 mg and 10 mg
showed significantly better results than placebo in meas-
ures of cognition (according to the AD Assessment Scale-
cognitive subscale [ADAS-cog] [24]; Figure 2) and global
function (according to the Clinician's Interview-Based Im-
pression of Change-plus Caregiver Input [CIBIC-plus]
[25]) [21–23]. In another open-label study over a period
of 254 weeks comparing donepezil to a historical placebo
(estimated from annualized changes in ADAS-cog from
historical cohorts of untreated AD patients), patients
treated with donepezil 10 mg/day maintained cognitive
function until Week 38 [26]. Benefits in ability to perform
ADL were also seen with donepezil 5 and 10 mg/day dur-
ing clinical use [21,22].
The long-term efficacy of donepezil has been examined in
three recently published 1-year trials [27–29]. One study
was a 1-year, placebo-controlled, function survival study
(n = 431) [27]. Donepezil extended the median time to
clinically evident functional decline (specifically defined
in the protocol) by 5 months compared with placebo.
Treatment with donepezil for 1 year was associated with a
38% reduction in risk of functional decline versus place-
Table 1: AChEI agents approved by the FDA: prescription share and prescription volume
Agent for AD Treatment Prescription Share Prescription Volume
Tacrine < 1% –
Donepezil ~66% ~530,000
Rivastigmine ~20% ~160,000
Galantamine ~14% ~110,000
Source: IMS NPA Audit via SMART, 2002 (annualized).
Table 2: Comparison of Features of Acetylcholinesterase Inhibitors (AChEIs)
AChEI (Binding) Mechanism of 
Action
Dosing 
Schedule
Recommended 
Daily Dosage 
Range
Half-life Comments
Tacrine (Non-competitive, 
reversible)
Inhibition of AChE 
Inhibition of 
BuChE
4 times daily 120–160 mg/day 
(Initial dose 40 mg/
day)
3–5 hours Used in the United States as a last-line 
agent due to its short half-life and high 
incidence of hepatotoxicity
Donepezil (Non-competitive 
reversible)
Inhibition of AChE Once daily 5–10 mg/day (Initial 
dose 5 mg/day)
70 hours Well tolerated, with positive effects 
on cognition, global function, and ADL
Rivastigmine (Non-competitive, 
reversible)
Inhibition of AChE 
Inhibition of 
BuChE
Twice daily 6–12 mg/day (Initial 
dose 3 mg/day)
1.5 hours Well tolerated, with positive effects 
on cognition, global function, and ADL
Galantamine (Competitive, 
reversible)
Inhibition of AChE 
Allosteric modula-
tion of nicotinic 
acetylcholine 
receptors
Twice daily 16–24 mg/day (Initial 
dose 8 mg/day)
7 hours Well tolerated, with positive effects 
on cognition, global function, ADL, 
behavior, and caregiver time
AChE, acetylcholinesterase; BuChE, butyrylcholinesterase; ADL, activities of daily living.Annals of General Hospital Psychiatry 2003, 2 http://www.general-hospital-psychiatry.com/content/2/1/1
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bo. In another 1-year, placebo-controlled study, patients
(n = 286) with mild-to-moderate AD treated with donepe-
zil showed benefits over placebo on global assessment,
cognition, and ADL over 1 year [28]. The third study pro-
vided 1-year data for donepezil comparing the rates of
cognitive decline after 1 year in patients with probable AD
treated with donepezil and those who remained untreated
[29]. Cognitive decline, based on change from baseline in
Mini-Mental State Examination (MMSE) scores, was sig-
nificantly slower in patients treated with donepezil com-
pared with untreated patients (p = 0.007). It is important
to note that the MMSE may not be the most accurate index
of the rate of cognitive decline [30]. As a result, while
MMSE scores are often used as study entry criteria, the
ADAS-cog is generally considered the gold standard by
regulatory agencies for assessing the effects of treatment
on cognition. The results from these three studies suggest
that donepezil is beneficial over at least the first year of
therapy; however, future studies are necessary to deter-
mine if these benefits extend beyond 1 year.
A recent study investigating the effect of donepezil treat-
ment on caregiver burden used a survey of AD caregivers
of patients treated with donepezil matched to AD caregiv-
ers of patients not treated with donepezil [31]. In the sur-
vey, time demands and distress linked to caregiving tasks
were rated. While caregivers of patients treated with
Figure 2
Cognitive function in AD patients receiving donepezil 5 or 10 mg/day or placebo [22]. Values are mean (± standard error of 
the mean [SEM]) change from baseline. Reassessment 6 weeks after withdrawal of donepezil reveals that the benefits of drug 
treatment were lost upon withdrawal. (From Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-
blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 1998;50:136-45.)Annals of General Hospital Psychiatry 2003, 2 http://www.general-hospital-psychiatry.com/content/2/1/1
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donepezil reported significantly less difficulties with car-
egiving, no differences in time demands were noted [31].
Rivastigmine
The third AChEI to be approved for use by the FDA, ri-
vastigmine, is prescribed in approximately 20% of all AD
cases [19]. Similar to tacrine [32], rivastigmine is a non-
competitive, reversible AChEI as well as an inhibitor of
BuChE (effects of inhibiting this enzyme on central nerv-
ous system cholinergic function are unknown) [14]. The
drug has a shorter half-life than that of donepezil, so it
must be administered twice daily. Effective doses range
from 6 to 12 mg/day. Gastrointestinal adverse events are
generally most common (Table 4), including weight loss
[33]; slow dose escalation and administration after meals
usually improve tolerability [34].
In two similarly designed double-blind, placebo-control-
led, 26-week trials, treatment with rivastigmine 1 to 4 mg/
day or 6 to 12 mg/day was studied for its effects on cogni-
tion, global function, and ability to perform ADL [33,35].
Patients in the high-dose group in each study showed sig-
nificant benefits over placebo in cognition (measured by
ADAS-cog; Figure 3), global function, and ability to
perform ADL. In an open-label extension of the earlier
study [33], patients originally in the higher-dose group
maintained cognitive function above baseline until Week
38; after that point, function declined but remained above
that of the patients in the lower-dose or placebo groups
[36].
Galantamine
Approved by the FDA in February 2001, galantamine is
the newest AChEI to be introduced. It is a novel drug with
a dual mechanism of action: competitive inhibition of
AChE and allosteric modulation of nicotinic receptors
(Figure 4) [14,37]. While the clinical significance of
nicotinic modulation for the treatment of AD may not be
fully elucidated, it is clear that nicotinic receptors play a
role in cognition. Presynaptic nicotinic receptors control
the release of neurotransmitters that are important for
memory and mood (eg, ACh, glutamate, serotonin, nore-
pinephrine) [38]. It has been shown that blocking nico-
tinic receptors impairs cognition [39], and selective
interaction with nicotinic receptor subtypes improves cog-
nitive function and memory [39,40].
Early evidence supports the nicotinic potentiating activity
of galantamine, in addition to its cholinesterase-inhibito-
ry properties [37,41]. The dual mechanism of action of
galantamine results in increased levels of ACh in the syn-
aptic cleft and increased effect at the nicotinic receptors
[14,37]. Increasing attention is being directed to deter-
mine whether nicotinic modulation confers neuroprotec-
tion [37]. Galantamine has been shown to be efficacious
in patients with previous exposure to other AchEIs [42].
Table 3: Adverse Events Associated With Donepezil*
Adverse Event† Placebo (n = 355) (%) Donepezil (n = 747) (%)
Nausea 6 11
Diarrhea 5 10
Insomnia 6 9
Vomiting 3 5
Muscle cramp 2 6
Fatigue 3 5
* Eisai Inc.: Aricept® (donepezil hydrochloride tablets) [package insert]. Teaneck, NJ 1998 †Occurring in at least 5% of patients and more often than 
in patients receiving placebo.
Table 4: Adverse Events Associated With Rivastigmine*
Adverse Event†
Placebo (n = 868) (%) Rivastigmine 6–12 mg/day (n = 1189) (%)
Nausea 12 47
Vomiting 6 31
Anorexia 3 17
Dyspepsia 4 9
Asthenia 2 6
* Novartis Pharmaceuticals Corp.: Exelon® (rivastigmine tartrate) capsules [prescribing information]. East Hanover, NJ 2001. † Occurring in at least 
5% of patients and at twice the placebo rate.Annals of General Hospital Psychiatry 2003, 2 http://www.general-hospital-psychiatry.com/content/2/1/1
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Galantamine has a relatively short half-life, so doses are
given twice daily. Recommended dosing is 16 mg/day,
with a maximum recommended dose of 24 mg/day [43–
45]. Adverse events associated with therapy are similar to
those seen with other AChEIs; the majority are gastroin-
testinal in nature (Table 5) [46]. Unlike donepezil, which
has been associated with an elevated incidence of insom-
nia and an increased use of hypnotic medications [47],
galantamine does not appear to be linked to sleep prob-
lems [48–50].
In multiple double-blind, placebo-controlled studies,
galantamine has shown promising effects on cognition,
global function, behavior, and ability to perform ADL
[45,46,51]. Patients treated with galantamine 24 mg/day
for 6 months showed significant improvements in cogni-
tion versus placebo and in comparison to baseline (Figure
5); global functioning either improved or remained sta-
ble, and ability to perform ADL did not change signifi-
cantly from baseline [51]. In a 6-month, open-label
extension, patients receiving galantamine 24 mg/day for
the entire 12 months maintained cognitive ability (Figure
5) and ability to perform ADL at baseline levels [51]. Pa-
tients who had received placebo for the first 6 months and
then switched to galantamine never achieved the level of
function seen in patients treated with galantamine
throughout, emphasizing the importance of early treat-
ment to maximize benefit [51]. In a 24-month, open-label
Figure 3
Cognitive function in AD patients receiving rivastigmine 1 to 4 or 6 to 12 mg/day or placebo [33]. Values represent mean 
change from baseline. Both doses of rivastigmine were superior to placebo, although the higher doses provided more benefit. 
(From Corey-Bloom J Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tar-
trate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease for the ENA 713 
B352 Study Group. Int J Geriatr Psychopharmacol. 1998;1:55-65.)Annals of General Hospital Psychiatry 2003, 2 http://www.general-hospital-psychiatry.com/content/2/1/1
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extension of two double-blind, placebo-controlled trials,
patients taking galantamine for the entire 36-month peri-
od continued to show cognitive benefits at 36 months
when compared with the expected decline of a historical
placebo group [52]. Thus, it appears that galantamine 24
mg/day provides cognitive benefits in patients who con-
tinue treatment compared with the expected natural
course of cognitive decline for up to 36 months.
Figure 4
Galantamine proposed mechanisms of action: acetylcholinesterase inhibition and allosteric nicotinic modulation [14,37].
Table 5: Adverse Events Associated With Galantamine [46]
Adverse Event* Placebo (n = 286) (%) Galantamine 16 mg/day (n = 
279) (%)
Galantamine 24 mg/day (n = 
273) (%)
Nausea 4.5 13.3 16.5
Vomiting 1.4 6.1 9.9
Anorexia 3.1 6.5 8.8
Agitation 9.4 10.0 8.1
Diarrhea 5.9 12.2 5.5
* Occurring in at least 5% of patients and more often than in patients receiving placebo.Annals of General Hospital Psychiatry 2003, 2 http://www.general-hospital-psychiatry.com/content/2/1/1
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In a 5-month, double-blind, placebo-controlled trial, a
slower dose-escalation schedule was used in an attempt to
improve tolerability [46]. Patients treated with galan-
tamine 16 or 24 mg/day showed significant improve-
ments in cognition over baseline and compared with
placebo. These same doses produced significant improve-
ments over placebo in ability to perform ADL (according
to the AD Cooperative Study Activities of Daily Living in-
ventory [ADCS/ADL], an assessment developed to meas-
ure the daily activities of patients with AD [53]) and in
behavioral symptoms (according to the Neuropsychiatric
Inventory [NPI], which assesses the frequency and severity
of symptoms in 10 behavioral domains [54]) [46].
Treatment with galantamine has also been shown to ease
caregiver burden [55]. Caregiver burden is defined as the
amount of time patients require supervision and assist-
ance with ADL. When caregiver time was measured with a
questionnaire documenting time spent supervising and
assisting with ADL, untreated patients required increased
supervision by the caregiver and increased assistance with
ADL over time, whereas patients treated with galantamine
for 6 months showed no significant change in time spent
by the caregiver on supervision. Caregiver assistance with
ADL decreased 61 minutes each day.
Figure 5
Cognitive function in AD patients receiving galantamine 24 mg/day for 12 months or placebo for 6 months followed by galan-
tamine 24 mg/day for 6 months [51]. Although patients who took galantamine 24 mg/day for 12 months were able to maintain 
cognitive function at baseline levels, patients who were on placebo for the first 6 months and then switched to galantamine 
could not achieve this level of functioning, indicating that early treatment provides the greatest benefit. (From Raskind MA, Pes-
kind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. 
Neurology. 2000;54:2261-8.)Annals of General Hospital Psychiatry 2003, 2 http://www.general-hospital-psychiatry.com/content/2/1/1
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Switching among different AChEIs
At present, there exist no clearly established guidelines for
determining which specific AChEI to use for which
specific patient with AD. Existing clinical trials data do not
help to inform this clinical decision making. By and large,
the magnitude of the treatment effect observed in the pub-
lished, placebo-controlled clinical trials for all of the
available agents is comparable. The side-effect profiles
differ in that rivastigmine, as an example, likely has more
gastrointestinal-related adverse events in therapeutic dos-
es than donepezil or galantamine. Donepezil appears to
have somewhat more sleep disturbance reported as a side
effect than the others. However, for reasons that are still
unclear, clinical experience dictates that some patients
will be idiosyncratically more tolerant of one agent than
another, or perhaps more responsive to one agent versus
another. With multiple therapies having become available
in the past few years for treatment of AD-related symp-
toms, this may prompt switches among AChEIs. Reasons
for switching among different AChEIs may include one or
more of the following: dosing convenience, inefficacy or
perceived inefficacy, poor tolerability, physician prefer-
ence, patient or caregiver request, or economic considera-
tions. Before a switch is made, the physician must
consider the pharmacodynamics and pharmacokinetics of
the possible options to maximize patient tolerability and
minimize loss of established efficacy from the previous
regimen.
A drug with a longer elimination half-life, such as donepe-
zil, may require a washout period of 1 to 2 weeks before
initiating another AChEI to avoid cholinergic toxicity
[56]. However, one must also consider that significant
functional decline may occur during washout, and
significant improvements achieved during therapy may be
lost during washout. If the latter occurs, restoring function
to pre-washout levels is rare if the drug is reinstated [56].
Three studies were done to determine the minimum
washout period necessary when switching from donepezil
to rivastigmine (1.5 mg twice daily) [57]. The first study
compared a 2-week washout (n = 5) versus no washout (n
= 6) of donepezil before rivastigmine was started. In the
second study, patients (n = 105) went through a 4-day
donepezil dose reduction, followed by a 4-day washout
before initiation of rivastigmine at 1.5 mg daily, and then
escalated based on tolerability. The third study compared
donepezil washout periods of zero days (n = 57), 3 days
(n = 2), and 4 weeks (n = 3). The results of these three
studies suggest that long washout periods may not be nec-
essary when switching from donepezil to rivastigmine
[57]. Larger studies are needed for verification of these
findings.
A post hoc analysis of a previously conducted trial [46]
was performed to examine the effect of prior AChEI expo-
sure on the efficacy and tolerability of galantamine [42].
There was a minimum 2-month washout period between
previous AChEI therapy and initiation of galantamine. Re-
gardless of previous AChEI exposure, treatment effects
were consistent with galantamine, with patients experi-
encing significant improvements in cognitive and global
function. There were no significant differences between
subgroups in terms of adverse events, indicating that
galantamine is well tolerated despite prior AChEI use
[42].
When determining the length of necessary washout, the
physician must weigh the risk for cognitive decline during
the washout period against the potential for adverse
events without a washout on a patient-by-patient basis
[56]. It is important to consider individual patient factors,
such as current cognitive abilities, health and frailty, use
of concomitant medications, potential for drug interac-
tions, and previous sensitivity to AChEI treatment [56].
When switching among AChEIs, the goal is to maintain
cognitive function while avoiding the emergence of
adverse events that may cause patients to discontinue
therapy [56].
Additional pharmacologic options
Vitamin E is an antioxidant that prevents cell damage by
inhibiting the oxidation of lipids and the formation of
free radicals. There is only one clinical trial investigating
its use in patients with AD [58]. Though it was safe and
well tolerated, there were no improvements in cognition,
function, or behavior. However, patients taking vitamin E
did show a significant treatment effect, specifically in the
delay of institutionalization [58]. The American Psychiat-
ric Association recommends the use of 1,000 IU of vita-
min E twice daily for patients with moderate AD.
Additional trials are needed to test the benefits of vitamin
E in patients with milder forms of AD.
Other alternative treatment agents that may have benefi-
cial effects in patients with AD are selegiline, ginkgo
biloba, and nonsteroidal anti-inflammatory drugs. Unfor-
tunately, within the nonsteroidal anti-inflammatory class,
recently concluded clinical trials of two selective COX-2
inhibitors, refecoxib and celecoxib, failed to show benefit
as therapeutic agents. However, based largely on epidemi-
ologic evidence, significant attention is still being directed
to whether nonselective agents such as indomethacin,
sulindac, and ibuprofen may have a role in the prevention
and treatment of AD. Recently, the statin class of com-
pounds as well as agents that lower serum homocysteine
levels (eg, folic acid) have been proposed for their possi-
ble therapeutic roles in the treatment of AD. More studies
need to be conducted before recommendations can be
made as to their appropriate use in the AD population.Annals of General Hospital Psychiatry 2003, 2 http://www.general-hospital-psychiatry.com/content/2/1/1
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Treatment of psychiatric and behavioral symptoms in AD
As the condition of patients with AD progressively deteri-
orates, they often develop behavioral symptoms that can
be very troublesome to the caregiver and/or family. Com-
mon psychiatric and behavioral symptoms frequently
seen include apathy, agitation, mood lability, blunted af-
fect, disinhibition, withdrawal, delusions, anxiety, suspi-
ciousness, dysphoria, hostility, aggression, and
hallucinations [59,60]. As severity increases, these symp-
toms can increase caregiver distress and often lead to
placement of the patient in a personal care facility [61].
Before treatment of these symptoms is begun, the physi-
cian must rule out any medical disorders, physical
discomfort, medication effects, or pre-existing psychiatric
illness that may be contributing factors. Once target be-
haviors are identified, appropriate treatment (pharmaco-
logic and/or environmental) can be initiated. While no
agents are currently approved for the treatment of behav-
ioral symptoms in patients with AD, physicians common-
ly prescribe off-label agents to help manage these
symptoms. Agents of choice include the atypical antipsy-
chotics (eg, risperidone, olanzapine, quetiapine), seroton-
ergic compounds (eg, citalopram, sertraline), or mood
stabilizers, such as sodium valproate. The best clinical trial
data gathered to date support the superior efficacy over
placebo of risperidone [62] and olanzapine [63] for psy-
chosis and agitation in dementia. Emerging placebo-con-
trolled data also support a role for sodium valproate [64]
in the treatment of agitation.
Importantly, the potential psychotropic effects of ChEIs
have also been increasingly explored. The cholinergic hy-
pothesis of the 1980s linked the changes in memory and
cognition seen in AD with biochemical changes in the
brain, changes that included deficits in acetylcholine,
norepinephrine, and serotonin. Treatment for AD in-
volved cholinomimetic therapies that block the
degradation of acetylcholine available at the synapse.
AChEIs were developed to delay the progression of cogni-
tive decline. The deficit in ACh is responsible for some of
the neuropsychiatric symptoms presented in AD – agita-
tion, psychosis, personality changes, depression – because
emotional behaviors are mediated by the effects of cholin-
ergic action on the frontal and temporal lobes of the
brain. AChEIs may create a more favorable neurochemical
environment allowing psychotropic agents to be more ef-
fective [65]. Clinical trials examining the psychotropic ef-
fects of these cholinomimetic drugs are being conducted
[16,65–69]. The positive effects that galantamine exhibits
on the behavioral aspects of AD illustrates multiple mech-
anisms by which this class of agents may exert psychotrop-
ic effects. One such mechanism is the action to increase
ACh: since patients with AD have low levels of ACh in the
limbic system [70], enhancing these levels with an AChEI
may help to improve behavioral symptoms. With galan-
tamine specifically, its nicotinic-modulatory property
may allow for increased arousal and decreased aberrant
motor behavior and agitation similar to the mechanism
by which psychostimulants act in the treatment of atten-
tion deficit disorders in children [71]. In addition, im-
proved function of nicotinic thalamofrontal projections
by galantamine may reduce agitation, which appears to be
frontally mediated [72].
Treatments in development
There are several new agents in development with various
mechanisms of action for the treatment of AD. The iden-
tification of new targets for AD treatment may allow for
combination therapy in the near future. While AChEIs are
the only approved treatment option for patients with AD,
researchers are currently studying other therapies.
Memantine (Merz & Co., Frankfurt/Main, Germany) is a
noncompetitive, N-methyl D-aspartate (NMDA) receptor
antagonist approved in Germany for more than 10 years
for the treatment of dementia. The proposed mechanism
by which memantine exerts its effects on dementia is
thought to be related to its neuroprotective characteristics
[73,74]. Clinical safety and efficacy have been investigated
both in clinical trials and postmarketing surveillance stud-
ies [75–77]. Memantine is generally well tolerated, with
the most common adverse events being vertigo, restless-
ness, hyperexcitation, and fatigue [76]. It may become a
neuroprotective treatment for dementias in the near fu-
ture, and it may also be combined with AChEIs for symp-
tomatic relief of AD [78].
An additional option for treatment of AD that has re-
ceived much attention is immunization against β-amyloid
to reduce the levels of β-amyloid plaques [79]; studies are
still in early development for its applicability to AD treat-
ment. Unfortunately, an ongoing clinical trial of one such
vaccine was recently halted due to the emergence of neu-
roinflammation in treated subjects. Other treatment pos-
sibilities include γ – and β-secretase inhibitors to prevent
β-amyloid formation [80].
Discussion
AD is a progressive disease that affects the patient's cogni-
tion, behavior, and function. Losses associated with the
disease have a profound impact on the patient and car-
egiver. Coping with this spectrum of change places an
enormous burden on family caregivers of patients with
AD. Diagnosis of the disease is the first important step,
since approximately 50% of patients with AD are not di-
agnosed, and only 50% of those diagnosed are being treat-
ed with some type of therapy [1]. Although there is no
cure for AD, it is a treatable disease. While treatment suc-
cess was traditionally defined as improvement fromAnnals of General Hospital Psychiatry 2003, 2 http://www.general-hospital-psychiatry.com/content/2/1/1
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baseline function, given that untreated patients with AD
show declines in cognition, ability to perform ADL, and
behavior, if drug treatment is able to improve function,
maintain baseline function over the long term, or allow
for a slower rate of functional decline, each of these out-
comes should be viewed as a treatment success. The cog-
nitive and functional benefits achieved with treatment
lead to improvement in caregiver burden, a parameter
that is very important but often overlooked.
While there is much ongoing research in the area of AD
treatment, there are currently four AChEIs available in the
United States: tacrine, donepezil, rivastigmine, and galan-
tamine. Although they are all members of the same drug
class, they have differences in their actions, dosing sched-
ules, and side-effect profiles. Results obtained with the use
of AChEIs clearly fit the updated definition of effective
treatment by improving or maintaining all domains of AD
(cognition, ADL, and behavior) in the short term, and by
slowing the decline in these functions through 12 months
of use or longer. It is important that physicians fully un-
derstand and clearly communicate to both the patient and
caregiver the expected outcomes of treatment on the dis-
ease process. Although prescribing atypical antipsychotics
and other agents for the management of behavioral symp-
toms associated with AD is not an FDA-approved practice,
this type of therapy can significantly decrease the severity
of these symptoms and may ease caregiver burden and
postpone institutionalization [61].
Conclusion
Early diagnosis and comprehensive treatment are crucial
in optimizing disease management. The most successful
treatment outcomes result from a firmly established part-
nership that encourages active communication between
the patient's caregiver and physician. AChEIs represent the
mainstay of the pharmacologic therapy of AD, yet the ef-
fects are largely symptomatic and may not prevent disease
progression. The beneficial effects that we do encounter
though modest are meaningful to many patients and their
families. We anticipate a future in which the practicing cli-
nician will prescribe agents that will not only slow the
clinical progression of the disease, but also restore cogni-
tive and behavioral functioning of the patient to premor-
bid levels, or best, prevent the development of AD in
susceptible persons. Potential targets for these evolving
therapeutics will likely include inflammation, neuropro-
tection, amyloid deposition, neurofibrillary tangle forma-
tion, and other important aspects of the pathogenesis of
AD.
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